Abstract: A process for producing basic aluminum magnesium carbonate, Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O, by carbonating an aluminum hydroxide (Al(OH).sub.3) and magnesium hydroxide aqueous reaction mixture with carbon dioxide in the presence of at least 6 moles of a base selected from the group consisting of ammonia, mono, di or trialkylamines, pyridine or piperidine, per mole of Al.sub.2 O.sub.3 present. The product is useful as an antacid.

Abstract: A new basic aluminium magnesium carbonate of the formula Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O has been found to be useful in pharmaceutical formulations for the treatment of upper gastrointestinal tract disturbances associated with excess acid and pepsin secretion or biliary reflux.

Abstract: This invention relates to piperidine derivatives. More particularly, the invention relates to substituted benzoic acid amides of N-substituted piperidine and to pharmaceutical compositions thereof, which are useful in antagonizing the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and in treating nausea and vomiting resulting from gastrointestinal disorders, congestive heart failure, post operative conditions, etc., other gastrointestinal disorders such as dyspepsia, flatulence, bile regurgitations, hiatus hernia, peptic ulcer, reflux aerophagitis, gastritis, duodenitis, and cholethiasis, and a variety of conditions affecting the central nervous system such as acute and chronic psychoses, maniacal psychosis, schizophrenias, serious disturbances of behavior and non-melancholic depressive state and migraine. The invention also relates to methods of preparing piperidine derivatives.

Abstract: The invention relates to aromatic amides N-substituted by heterocyclic groups. More particularly, the invention relates to substituted benzoic acid amides of 1-arylalkylamino or aminoalkyl-N-heterocyclic rings and to pharmaceutical compositions thereof, which have the ability to antagonize the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and which may be used for the treatment of nausea and vomiting resulting from gastrointestinal disorders, congestive heart failure, post operative conditions, etc., other gastrointestinal disorders such as dyspepsia, flatulence, bile regurgitations, hiatus hernia, peptic ulcer, reflux aerophagitis, gastritis, duodenitis, and cholethiasis, and a variety of conditions affecting the central nervous system such as acute and chronic psychoses, maniacal psychosis, schizophrenias, serious disturbances of behavior and non-melancholic depressive state and migraine.